oral polio vaccine

oral polio vaccine. The oral polio vaccine (OPV) is a live-attenuated vaccine used to prevent poliomyelitis, a disease caused by the poliovirus. Developed primarily by Albert Sabin, it was first licensed in the early 1960s and became the cornerstone of global immunization programs due to its ease of administration and ability to induce intestinal immunity. The vaccine contains weakened strains of the three serotypes of poliovirus and is administered orally, typically in multiple doses.

History and development

The development of the oral polio vaccine was pioneered by Albert Sabin in the late 1950s, building upon earlier work with live viruses by researchers like Hilary Koprowski and Herald Cox. Sabin's strains were attenuated through serial passage in non-human tissue cultures, a method distinct from the inactivated approach used by Jonas Salk. Large-scale clinical trials, including significant studies in the Soviet Union and Eastern Europe, demonstrated its safety and efficacy. The vaccine was licensed in the United States in 1961 and quickly adopted by the World Health Organization for use in mass immunization campaigns, supplanting the Salk vaccine in many parts of the world due to its logistical advantages and lower cost.

Mechanism of action

The vaccine contains live, attenuated strains of poliovirus types 1, 2, and 3. After oral administration, these weakened viruses replicate in the intestinal tract, stimulating the production of secretory IgA antibodies at the primary site of wild poliovirus entry. This local immune response provides mucosal immunity, which is critical for interrupting person-to-person transmission. Additionally, the replication induces a robust systemic immune response, generating circulating IgG antibodies that protect against paralytic polio by preventing viral spread to the central nervous system. The vaccine viruses are also excreted for a period, which can lead to passive immunization of close contacts in communities with poor sanitation.

Efficacy and safety

The oral polio vaccine is highly effective, providing greater than 90% immunity against all three poliovirus serotypes after three doses. It has been instrumental in eliminating wild poliovirus from most countries, including the Americas, which was certified polio-free by the Pan American Health Organization in 1994. A rare but significant safety concern is the occurrence of vaccine-associated paralytic poliomyelitis (VAPP), caused by reversion of the attenuated virus to a neurovirulent form. Additionally, in areas with very low vaccination coverage, circulating vaccine-derived poliovirus (cVDPV) can emerge from prolonged transmission of the excreted vaccine virus. These risks have shaped modern immunization strategies.

Administration and schedule

The vaccine is administered orally, typically as two drops delivered directly into the mouth from a multidose vial, requiring no needles or trained medical personnel for basic delivery. The standard immunization schedule recommended by the World Health Organization involves a primary series of three doses, starting at birth or at 6 weeks of age, with subsequent booster doses during supplementary immunization activities. Mass administration is often coordinated through National Immunization Day campaigns, which can vaccinate millions of children in a single day. The ease of this method has been pivotal for reaching children in remote areas and during conflicts, such as in Afghanistan and Pakistan.

Global eradication efforts

The oral polio vaccine has been the principal tool in the Global Polio Eradication Initiative, a public health campaign launched in 1988 and led by the World Health Organization, UNICEF, the Centers for Disease Control and Prevention, and Rotary International. Its ability to induce herd immunity and be deployed rapidly in mass campaigns has reduced endemic wild poliovirus transmission to only two countries: Afghanistan and Pakistan. A major strategic shift occurred with the globally synchronized withdrawal of the type 2 component in 2016, switching from the trivalent vaccine to a bivalent formulation to eliminate the risk from type 2 cVDPVs. Ongoing challenges include reaching every child in conflict zones and maintaining high coverage to prevent outbreaks.

Comparison with inactivated polio vaccine

The inactivated polio vaccine, developed by Jonas Salk, is administered via injection and contains virus particles killed by formalin. Unlike the oral vaccine, IPV cannot replicate, carries no risk of VAPP or generating cVDPVs, and is considered safer for immunocompromised individuals. However, IPV induces weaker intestinal immunity, making it less effective at halting fecal-oral transmission in communities, a critical factor for eradication. Most high-income countries, such as the United States and those in Western Europe, now use exclusive IPV schedules, while many eradication programs use a sequential schedule, starting with IPV followed by OPV to balance safety and population immunity. Category:Vaccines Category:Poliomyelitis